{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:20:00Z","timestamp":1780449600100,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03072-9","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T11:47:46Z","timestamp":1734349666000},"page":"918-934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis"],"prefix":"10.1007","volume":"42","author":[{"given":"Gilwan","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen","family":"Zakharyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Durica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Wallem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Viktrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"3072_CR1","unstructured":"Ruschel map, jesus od. Migraine headache [updated 2023 Aug 23]. Treasure Island (fl): Statpearls publishing; available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/nbk560787\/ (Statpearls [internet]). Accessed Jan 2024."},{"issue":"7","key":"3072_CR2","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1007\/s00415-023-11706-1","volume":"270","author":"F Puledda","year":"2023","unstructured":"Puledda F, Silva EM, Suwanlaong K, Goadsby PJ. Migraine: from pathophysiology to treatment. J Neurol. 2023;270(7):3654\u201366.","journal-title":"J Neurol"},{"issue":"2","key":"3072_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","volume":"19","author":"TJ Steiner","year":"2023","unstructured":"Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol. 2023;19(2):109\u201317.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"3072_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/head.12482","volume":"55","author":"RC Burch","year":"2015","unstructured":"Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: Updated statistics from government health surveillance studies. Headache. 2015;55(1):21\u201334.","journal-title":"Headache"},{"issue":"4","key":"3072_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000002790","volume":"8","author":"HZ Law","year":"2020","unstructured":"Law HZ, Chung MH, Nissan G, et al. Hospital burden of migraine in United States adults: A 15-year national inpatient sample analysis. Plast Reconstr Surg Glob Open. 2020;8(4): e2790.","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"5","key":"3072_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343\u20139.","journal-title":"Neurology"},{"issue":"3","key":"3072_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/head.12074","volume":"53","author":"TA Smitherman","year":"2013","unstructured":"Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache. 2013;53(3):427\u201336.","journal-title":"Headache"},{"key":"3072_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2022.100408","volume":"27","author":"DO de Begasse","year":"2022","unstructured":"de Begasse DO, Sakai F. Migraine in the workplace. eNeurolSci. 2022;27: 100408.","journal-title":"eNeurolSci."},{"issue":"5","key":"3072_CR9","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/head.13275","volume":"58","author":"M Bonafede","year":"2018","unstructured":"Bonafede M, Sapra S, Shah N, et al. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache. 2018;58(5):700\u201314.","journal-title":"Headache"},{"issue":"12","key":"3072_CR10","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.37765\/ajmc.2020.88547","volume":"26","author":"A Yucel","year":"2020","unstructured":"Yucel A, Thach A, Kumar S, et al. Estimating the economic burden of migraine on us employers. Am J Manag Care. 2020;26(12):e403\u20138.","journal-title":"Am J Manag Care"},{"key":"3072_CR11","unstructured":"Mrf migraine research foundation. Migraine fact sheet New York, NY: Migraine research foundation; 2016 [cited 2024]. Available from: https:\/\/migraineresearchfoundation.org\/about-migraine\/migraine-facts\/. Accessed Jan 2024."},{"issue":"5","key":"3072_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/head.14721","volume":"64","author":"DC Buse","year":"2024","unstructured":"Buse DC, Sakai F, Matharu M, et al. Characterizing gaps in the preventive pharmacologic treatment of migraine: multi-country results from the CaMEO-I study. Headache. 2024;64(5):469\u201381.","journal-title":"Headache"},{"issue":"5","key":"3072_CR13","doi-asserted-by":"publisher","first-page":"E187","DOI":"10.1503\/cmaj.221607","volume":"195","author":"V Tzankova","year":"2023","unstructured":"Tzankova V, Becker WJ, Chan TLH. Pharmacologic prevention of migraine. CMAJ. 2023;195(5):E187\u201392.","journal-title":"CMAJ"},{"issue":"4","key":"3072_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American headache society position statement update. Headache. 2024;64(4):333\u201341.","journal-title":"Headache"},{"key":"3072_CR15","unstructured":"U.S. Food and Drug Administration. Emgality\u00ae (galcanezumab-gnlm) injection, for subcutaneous use. Initial U.S. Approval: 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761063s006lbl.pdf. Accessed Jul 2024."},{"key":"3072_CR16","unstructured":"U.S. Food and Drug Administration. Nurtec\u00ae ODT (rimegepant) orally disintegrating tablets, for sublingual or oral use. Initial U.S. Approval: 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/212728s009lbl.Pdf. Accessed Jul 2024."},{"issue":"4","key":"3072_CR17","doi-asserted-by":"publisher","first-page":"333102423115936","DOI":"10.1177\/03331024231159366","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, et al. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023;43(4):3331024231159366.","journal-title":"Cephalalgia"},{"issue":"1","key":"3072_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40120-023-00562-w","volume":"13","author":"TJ Schwedt","year":"2024","unstructured":"Schwedt TJ, Myers Oakes TM, Martinez JM, et al. Comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine: results from a randomized, controlled clinical trial. Neurol Ther. 2024;13(1):85\u2013105.","journal-title":"Neurol Ther"},{"issue":"5","key":"3072_CR19","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1007\/s12325-020-01319-9","volume":"37","author":"V Martin","year":"2020","unstructured":"Martin V, Samaan KH, Aurora S, et al. Efficacy and safety of galcanezumab for the preventive treatment of migraine: a narrative review. Adv Ther. 2020;37(5):2034\u201349.","journal-title":"Adv Ther"},{"key":"3072_CR20","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.2147\/PPA.S435782","volume":"17","author":"OJ Varnado","year":"2023","unstructured":"Varnado OJ, Gulati T, Wheeler A, Hoyt M. Treatment patterns, healthcare resource utilization, and direct costs among patients initiating concomitant use of a calcitonin gene-related peptide monoclonal antibody (CGRP mAb) and novel acute medication in the United States. Patient Prefer Adherence. 2023;17:3449\u201359.","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"3072_CR21","first-page":"818","volume":"28","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, et al. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs. other preventive migraine treatments in the United States. J Manag Care Spec Pharm. 2022;28(8):818\u201329.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"3072_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","volume":"54","author":"ST Normand","year":"2001","unstructured":"Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54(4):387\u201398.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"3072_CR23","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/head.14527","volume":"63","author":"Z Ahmed","year":"2023","unstructured":"Ahmed Z, Honomichl R, Thompson SF, et al. Clinical characteristics and patient-reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: a retrospective observational study. Headache. 2023;63(7):908\u201316.","journal-title":"Headache"},{"key":"3072_CR24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/PPA.S346660","volume":"16","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Manjelievskaia J, Ye W, et al. Treatment patterns for calcitonin gene-related peptide monoclonal antibodies including galcanezumab versus conventional preventive treatments for migraine: a retrospective US claims study. Patient Prefer Adherence. 2022;16:821\u201339.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"3072_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s10194-019-1031-y","volume":"20","author":"A Vivekanantham","year":"2019","unstructured":"Vivekanantham A, Edwin C, Pincus T, et al. The association between headache and low back pain: a systematic review. J Headache Pain. 2019;20(1):82.","journal-title":"J Headache Pain"},{"issue":"1","key":"3072_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s10194-023-01678-y","volume":"24","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Urman R, Gill K, et al. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway. J Headache Pain. 2023;24(1):153.","journal-title":"J Headache Pain"},{"issue":"3","key":"3072_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40261-024-01345-3","volume":"44","author":"R Thaliffdeen","year":"2024","unstructured":"Thaliffdeen R, Yu A, Rascati K. Cost-effectiveness evaluation of oral CGRP antagonists, atogepant and rimegepant, for the preventative treatment of episodic migraine: results from a us societal perspective model. Clin Drug Investig. 2024;44(3):209\u201317.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"3072_CR28","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470\u201385.","journal-title":"Cephalalgia"},{"issue":"11","key":"3072_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038972","volume":"10","author":"V Orlando","year":"2020","unstructured":"Orlando V, Mucherino S, Monetti VM, et al. Treatment patterns and medication adherence among newly diagnosed patients with migraine: a drug utilisation study. BMJ Open. 2020;10(11): e038972.","journal-title":"BMJ Open"},{"issue":"1","key":"3072_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-022-01448-2","volume":"23","author":"P Irimia","year":"2022","unstructured":"Irimia P, Garcia-Azorin D, Nunez M, et al. Persistence, use of resources and costs in patients under migraine preventive treatment: The PERSEC study. J Headache Pain. 2022;23(1):78.","journal-title":"J Headache Pain"},{"issue":"4","key":"3072_CR31","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644\u201355.","journal-title":"Headache"},{"key":"3072_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.788159","volume":"12","author":"L Mechtler","year":"2021","unstructured":"Mechtler L, Saikali N, McVige J, et al. Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to onabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine. Front Neurol. 2021;12: 788159.","journal-title":"Front Neurol"},{"issue":"9","key":"3072_CR33","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/head.14386","volume":"62","author":"LT Hubig","year":"2022","unstructured":"Hubig LT, Smith T, Chua GN, et al. A stated preference survey to explore patient preferences for novel preventive migraine treatments. Headache. 2022;62(9):1187\u201397.","journal-title":"Headache"},{"key":"3072_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/jcm11154359","volume":"11","author":"GR Nissan","year":"2022","unstructured":"Nissan GR, Kim R, Cohen JM, et al. Reducing the burden of migraine: safety and efficacy of CGRP pathway-targeted preventive treatments. J Clin Med. 2022;11:15.","journal-title":"J Clin Med"},{"issue":"1","key":"3072_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s10194-023-01539-8","volume":"24","author":"L Al-Hassany","year":"2023","unstructured":"Al-Hassany L, Lyons HS, Boucherie DM, et al. The sense of stopping migraine prophylaxis. J Headache Pain. 2023;24(1):9.","journal-title":"J Headache Pain"},{"issue":"4","key":"3072_CR36","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1111\/1475-6773.12020","volume":"48","author":"JM Brooks","year":"2013","unstructured":"Brooks JM, Ohsfeldt RL. Squeezing the balloon: propensity scores and unmeasured covariate balance. Health Serv Res. 2013;48(4):1487\u2013507.","journal-title":"Health Serv Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03072-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03072-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03072-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:53:18Z","timestamp":1738407198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03072-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3072"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03072-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gilwan Kim, Margaret Hoyt, Jennifer Durica, Alexandra Wallem, and Lars Viktrup are employees and minor stockholders of Eli Lilly and Company. Armen Zakharyan is an employee of TechData Service Company, LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Institutional review board approval to conduct this study was not required, as the study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data provided at .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}